FRITZ-BENDER-FOUNDATION/VHIO INTERNATIONAL SYMPOSIUM

17 Fritz Bender Foundation International Symposium-vhio

Please note: this is VHIO´s landing page for this forthcoming meeting. For all information including Abstract Submission, Registration and Accommodation visit the official symposium web page: www.vhiosymposium2013.com.

Symposium Synopsis

Marking the 17th international symposium in the annual series of prestigious meetings organized by the Fritz Bender Foundation, we are delighted to announce that Progress Towards Individualized Cancer Treatments will take place from 07 – 09 November 2013, hosted by VHIO.

FINAL CHANCE TO REGISTER BEFORE 05 NOVEMBER ONLINE AT:  www.vhiosymposium2013.com

Incorporating an outstanding panel of internationally renowned speakers, we can all look forward to two and a half days´ debate and exchange of the highest degree across the five main sessions: 1) Genetic Profiling of Patients, 2) Tumor Characterization, 3) Tumor-Host Relationships, 4) Therapeutic Targets I, and 5) Therapeutic Targets II.

In addition to the main scientific program, which will undoubtedly address some of the many remaining questions in our relentless efforts to change the face of cancer through precision cancer treatment and care, we can also expect to discover yet more relevant and recent advances within our field throughout the poster and networking sessions scheduled throughout the coffee and lunch breaks.

Some 60 posters will be divided and displayed across the first two days of the meeting, with their respective author(s) present to discuss the findings directly with us all. In recognition of these contributions, in collaboration with VHIO, both Nature Reviews Cancer and Nature Reviews Clinical Oncology have each sponsored a poster prize. To be judged by our Scientific Committee: Symposium Co-Chairs, Josep Tabernero, Director of VHIO and VHIO´s Clinical Research Program, Kurt S. Zaenker, the Fritz Bender Foundation and the University of Witten/Herdecke (Germany), Enrico Mihich, the Dana Farber Cancer Institute (USA), as well as Joaquín Arribas and Joan Seoane, Directors of VHIO´s Preclinical and Translational Research Programs, the prizes will be awarded to the presenters of the two top posters on the last day of the Symposium, Saturday 09 November.

All registered participants are also warmly invited to our Symposium Cocktail Reception. To commence straight after the close of sessions on Thursday 07 November, we will be enjoying an aperitif complete with traditional culinary delights and musical entertainment to be performed by one of our Symposium participants!

We look forward to joining you all for a meeting par excellence to both match and celebrate the successes of past Fritz Bender Foundation International Symposia.

Symposium Co-Chairs:

Josep Tabernero, Vall d´Hebron Institute of Oncology (Spain)

Kurt S. Zaenker, Fritz Bender Foundation & University of Witten/Herdecke (Germany)

Enrico Mihich, Dana Farber Cancer Institute (USA)

Symposium Co-Chairs:

  • Josep Tabernero, Vall d´Hebron Institute of Oncology (Spain)
  • Kurt S. Zaenker, Fritz Bender Foundation & University of Witten/Herdecke (Germany)
  • Erico Mihich, Dana Farber Cancer Institute (USA)

Scientific Program

PLEASE NOTE: The Scientific Program will be regularly updated. Please bookmark and visit  www.vhiosymposium2013.com for all the latest information.

Day 1: Thursday 07 November 2013

  • Welcome/Opening Address: 09:00 – 09:15
  • Enrico Mihich (USA) & Josep Tabernero (Spain)
  • Keynote Address: 09:15 – 10:00
  • Geoff Wahl (USA)

Dissecting Breast Cancer Through the Lens of Development; New Opportunities for Targeted Therapeutics

SESSION I: GENETIC PROFILING OF PATIENTS

Chair: Marco Pierotti (Italy)

10:00 – 13:15

1) Marco Pierotti (Italy) 10:00 – 10:40

Genetic Heterogeneity of Individuals at Increased Risk of Breast Cancer: Challenges for Clinical Exploitation

2) Hege E. Giercksky Russnes (Norway) 10:40 – 11:20

Inter- and Intra-Tumoral Heterogeneity of Breast Cancer; Diagnostic and Therapeutic Implications

Coffee/Posters 11:20 – 11: 35

3) Barrett Rollins (USA) 11:35 – 12:15

PROFILE: An Enterprise-Level Genomic Testing Program for Research and Clinical Care

SELECTED SHORT TALK: Thomas Dittmar (Germany) 12:15 – 12:35
Altered miRNA expression profile in hybrid cells derived from breast cancer cells and cells with stem cell properties 

Meet the Expert with Julio Celis (Denmark) 12:35 – 13:15

Coordination of Cancer Research in Europe: Challenges & Opportunities

LUNCH/POSTERS/NETWORKING 13:15 – 14:15

SESSION II: TUMOR CHARACTERIZATION

Chair: Joan Seoane (Spain)

14:15 – 18:10

1) Joan Seoane (Spain ) 14:15 – 14:55

Intra-Tumoral Heterogeneity in Brain Tumors

2) Manel Esteller (Spain) 14:55 – 15:35

Cancer PharmacoEpigentics: Genes & Drugs

3) Frank Thevenod (Germany) 15:35 – 16:15

Pituitary homeobox 2 (PITX2): A Novel Transcription Factor Mediating Drug Resistance in Cancer Cells by Upregulation of Multi-Drug Resistance P-Glycoprotein (ABCB1) 

Coffee/Posters 16:15 – 16:30

4) Maria Blasco (Spain) 16:30 – 17:10

Telomeres & Cancer

5) Carlos Caldas (UK) 17:10 – 17:50

The Genomic Characterization of Breast Cancer: Not One Disease but Ten Distinct Entities

6) Manuel Hidalgo (Spain) 17:50 – 18:30

Integrating PDX Models in Personalized Medicine Strategies     

7) Stefano Piccolo (Italy) 18:30 – 19:10

Beyond Hippo Signaing: Role of YAP & TAZ as Mecahnotransducers in Cancer

SELECTED SHORT TALK: Cristina Bernadó (Spain) 19:10 – 19:30
Mechanisms behind the Oncogene Induced Senescence (OIS) – Oncogene Induced Apoptosis (OIA) decision in cells expressing p95HER2 

SYMPOSIUM COCKTAIL/RECEPTION 19:30 –

Day 2: Friday 08 November 2013

SESSION III: TUMOR-HOST RELATIONSHIPS

Chair: Joaquín Arribas (Spain)

09:00 – 12:55

1) Olivera J. Finn (USA) 09:00 – 09:40

Therapeutic and Prophylactic Cancer Vaccines: the Original and Ultimate Personalized Cancer Treatment

2) Paola Allavena (Italy) 09:40 – 10:20

Targeting Tumor-Promoting Inflammation

Coffee/Posters 10:20 – 10:35

3) Soldano Ferrone (USA) 10:35 – 11:15

Antibody-Based Immunotherapy of Malignant Disease, Cancer Initiating Cells and Disease Recurrence

4) Federico Garrido (Spain) 11:15 – 11:55

MHC Antigens and Tumor Immune Escape

5) Joaquín Arribas (Spain) 11:55 – 12:35

Oncogene Induced Senescence During Breast Cancer Progression and Treatment

SELECTED SHORT TALK: Sandra Peiró 12:35 – 12:55
Regulation of Heterochromatin Transcription By Snail1/ LOXL2 During Epithelial to Mesenchymal Transition 

LUNCH/POSTERS/NETWORKING 12:55 – 14:00

SESSION IV: THERAPEUTIC TARGETS I

Chair: Antoni Ribas (USA)

14:00 – 17:55

1) Peter Jones (USA) 14:00 – 14:40

Targeting DNA Methylation Alterations in Cancer

2) Rafaella Giavazzi (Italy) 14:40 – 15:20

Targeting Angiogenesis in Ovarian Cancer

3) Levi Garraway (USA)  15:20 – 16:00

Systematic Studies of Cancer Genetics and Therapeutic Resistance

Coffee/Posters 16:00 – 16:15

4) Joe Gray (USA) 16:15 – 16:55

A Multiscale Architechtural Analysis of Cancer Genome Aberration Function

5) Michelle Garrett (UK) 16:55 – 17:35

Cancer Drug Discovery: From Therapeutic to Clinic

SELECTED SHORT TALK: Martin A. Rivas (Spain) 17:35 – 17:55
Sensitivity to combined MEK and mTORC1/2 inhibition in colorectal cancer is dictated by p53 mutational status

Meet the Expert with Gerard Evan (UK) 17:55 – 18:35

Choosing a Career in Cancer Research: Challenges and Rewards

Day 3 (half day): Saturday 09 November 2012

SESSION V: THERAPEUTIC TARGETS II

Chair: Josep Tabernero (Spain)

09:00 – 12:15

1) Neal Rosen (USA) 09:00 – 09:40

Oncogene Dependence Seed Back: Basic and Clinical Implications

2) Mina Bissell (USA) 09:40 – 10:20

Three Dimensional Models to Screen for Effective Drugs & for Understanding Where Dormant Cells Go in Breast Cancer & How Do They Wake Up to Metastasize

Coffee 10:20 – 10:35

4) Antoni Ribas (USA) 10:35 – 11:15

Building on the Success of BRAF Inhibitors & Immunotherapy for Melanoma

5) Josep Tabernero (Spain) 11:15 – 11:55

Dissecting CRC in Multiple, Targetable Diseases

SELECTED SHORT TALK: Cristina Puig-Saus (Spain) 11:55 – 12:15
iRGD (tumor-penetrating peptide)-modified oncolytic adenovirus shows enhanced antitumor efficacy

Summary     Kurt Zaenker (Germany) 12:15 – 13:00

POSTER PRIZE WINNERS ANNOUNCED AND AWARDED

Lunch & Departure

Registration & Abstract Submission

Please note: this is VHIO´s landing page for this forthcoming meeting. For all information including Abstract Submission, Registration, and Accommodation visit the official symposium web page: www.vhiosymposium2013.com.

We are delighted to announce that Nature Reviews Cancer and Nature Reviews Clinical Oncology will each sponsor a poster prize at the forthcoming VHIO-Fritz Bender Foundation joint International Symposium on Progress Towards Individualized Cancer Treatments, 07 – 09 November 2013, Barcelona, Spain. To be judged by our Scientific Committee, the prizes will be awarded to the presenters of the two top posters showcased during the meeting.

To view the Scientific Program, discover the many topics to be discussed and debated by our expert panel of internationally renowned speakers, and submit your abstract visit: http://www.vhiosymposium2013.com.

           Registration closes 05 November 2013

Registration covers access to all symposium sessions, the Program & Abstract Book, the symposium cocktail reception (immediately following close of final session on Thursday 07 November 2013 as of 19:00h), coffee breaks and buffet lunches (poster and networking sessions).

Registration fees 

Early registration fees(deadline 30/09/2013) Regular registration fee(deadline 05/11/2013)
Students  (including PhD Students) 160 EUR 200 EUR
Academic 200 EUR 250 EUR
Industry 240 EUR 300 EUR

 

Please note: registration does not include accommodation. Each participant must organize his/her own accommodation. For information about the official Symposium hotel and alternative accommodation situated close by to the symposium venue, click here, or visit: www.vhiosymposium2013.com.

Dates for the Diary & Symposium Venue
Final registration closes: 05 November 2013

Symposium Venue:

Pabellón Docente Auditorium

The Vall d´Hebron University Hospital

Natzaret Street with Arquitectura St.

08035 Barcelona, Spain

Accommodation

Please note: registration does not include accommodation. Each participant must organize his/her own accommodation. For information about the official Symposium hotel and alternative accommodation situated close by to the symposium venue, click here, or visit: www.vhiosymposium2013.com.

Contact

For all queries concerning registration and/or abstract submission, recommended options regarding accommodation,  please contact our officially appointed scientific event logistics company, OMINIPREX S.L. directly:

OMNIPREX© INTERNATIONAL GROUP